Cupid Q1 FY27: Revenue Up 142% to ₹157 Cr, Net Profit Jumps 194% to ₹44 Cr; FY27 Guidance Raised
Cupid Limited reported a 142% YoY increase in total income to ₹156.98 crore and a 194% YoY jump in Net Profit to ₹44.15 crore for Q1 FY27. The company upgraded its FY27 guidance to ₹725-₹750 crore revenue and ₹210-₹225 crore net profit. The Palava manufacturing facility is set for Q2 FY27 commissioning.
The substantial year-on-year growth in key financial metrics, coupled with an upgraded full-year guidance and progress on manufacturing capacity expansion, is expected to have a significant positive impact on investor sentiment and the company's valuation.
The company reported significant year-on-year growth in revenue and net profit, along with an upgrade in its financial guidance for the fiscal year, indicating strong operational performance and positive future outlook.
Cupid Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting a strong start to FY27. The company's total income surged by 142% year-on-year to ₹156.98 crore, while operating income grew by an impressive 159% to ₹154.72 crore. EBITDA saw a substantial increase of 265% to ₹60.06 crore, with EBITDA margin expanding by 1,127 basis points to 39%. Profit Before Tax (PBT) rose by 206% to ₹59.92 crore, and Net Profit soared by 194% to ₹44.15 crore.
The company attributed this robust performance to continued business momentum and improved visibility across its international B2B healthcare and domestic Consumer Healthcare & FMCG businesses. Strong demand in the international B2B healthcare segment, including PFSCM, WHO/UNFPA, and government tenders, contributed significantly. Cupid has also implemented a minimum 10% price increase across its export portfolio and benefited from a favorable USD/INR environment.
Buoyed by these results and a strong order book, Cupid has upgraded its FY27 guidance. The company now expects revenue between ₹725 crore and ₹750 crore, and Net Profit between ₹210 crore and ₹225 crore. This revised outlook reflects management's confidence in sustained performance, supported by manufacturing expansion and strategic initiatives.
The Palava manufacturing facility is on schedule for commissioning during Q2 FY27, which will significantly enhance production capabilities with an annual capacity for approximately 1.25 billion male condoms and 125 million female condoms. Strategic investments in Baazar Style Retail and GII Healthcare are also expected to be value accretive.
Mr. Aditya Kumar Halwasiya, Chairman and Managing Director, expressed optimism about the company's growth trajectory, highlighting the strong execution, improving order visibility, and the expansion of both B2B healthcare and Consumer Healthcare & FMCG businesses. He emphasized the role of the upcoming Palava facility and strategic investments in driving long-term value creation.
What to do with a filing like this
Cupid Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cupid Limited. Read the original for the full detail.